Table 3.
Frequencies of genetic variants in the calcium-toolkit encoding genes documented in lymphoid and myeloid cancer databases.
| Cancer type | Lymphoid | Myeloid | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| B-cell | T-cell | AML | MDS | MPN | |||||||
| B-ALL | DLBCL | Low-grade B-cell neoplasms | Low-grade T-cell neoplasms | ||||||||
| Total | CLL | MBL | MCL | PCM | |||||||
| Total number of patients per cancer type | 234 except 1269 | 1288 | 1542 | 1254 | 54 | 29 | 205 | 43 | 821 | 31 except 2209 3431 433 | 151 |
| Gene sets analyzed | % of patients with gene variants in each cancer type | ||||||||||
| CACNA | 0.0 | 3.8 | 2.8 | 2.2 | 5.6 | 0.0 | 6.3 | 9.3 | 1.8 | 0.0 | 2.0 |
| TRPC | 0.4 | 2.6 | 2.1 | 2.3 | 1.9 | 0.0 | 1.5 | 11.6 | 1.1 | 3.2 | 2.0 |
| TRPV | 0.4 | 0.3 | 0.8 | 0.6 | 0.0 | 3.4 | 2.0 | 4.7 | 0.7 | 0.0 | 0.0 |
| TRPM | 0.4 | 2.7 | 2.6 | 1.9 | 3.7 | 10.3 | 5.4 | 11.6 | 2.2 | 3.2 | 0.7 |
| VDAC | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| GRIN | 1.3 | 1.6 | 0.9 | 0.8 | 0.0 | 3.4 | 1.5 | 9.3 | 1.1 | 1.02 | 2.0 |
| P2RX | 0.0 | 0.7 | 0.3 | 0.2 | 0.0 | 0.0 | 1.0 | 4.7 | 0.1 | 0.0 | 0.7 |
| nAChR | 0.4 | 0.9 | 1.2 | 0.8 | 1.9 | 3.4 | 3.4 | 4.7 | 0.7 | 0.0 | 0.0 |
| PIEZO | 0.0 | 0.4 | 0.5 | 0.5 | 0.0 | 0.0 | 0.5 | 0.0 | 0.2 | 0.0 | 0.0 |
| ORAI | 0.0 | 0.4 | 0.3 | 0.1 | 0.0 | 0.0 | 2.0 | 0.0 | 0.5 | 0.0 | 0.7 |
| STIM | 0.4 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| ITPR | 1.3 | 1.4 | 0.8 | 0.6 | 1.9 | 0.0 | 2.0 | 2.3 | 0.5 | 0.0 | 0.7 |
| RYR | 0.4 | 2.5 | 4.5 | 3.8 | 0.0 | 0.0 | 10.2 | 7.0 | 0.6 | 0.0 | 0.7 |
| SERCA | 0.01 | 1.2 | 1.6 | 1.4 | 3.7 | 0.0 | 2.0 | 4.7 | 1.5 | 3.2 | 0.7 |
| Calcium exchangers | 0.0 | 1.2 | 1.4 | 1.1 | 1.9 | 0.0 | 2.9 | 14.0 | 0.9 | 3.2 | 0.0 |
| Mitochondrial calcium regulators | 0.0 | 0.5 | 0.6 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| Endolysosomal calcium channels | 0.4 | 0.7 | 0.5 | 0.3 | 0.0 | 3.4 | 1.0 | 2.3 | 0.4 | 0.0 | 0.0 |
| CALR | 0.0 | 0.2 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 1.43 | 16.6 |
| Calcium binders | 0.01 | 1.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.5 | 0.0 | 0.2 | 0.0 | 0.0 |
| S100 family | 0.4 | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| PKC | 0.0 | 1.9 | 1.4 | 1.2 | 0.0 | 0.0 | 3.4 | 2.3 | 0.6 | 0.04 | 0.7 |
| CAMK | 0.0 | 0.8 | 1.0 | 0.9 | 0.0 | 0.0 | 2.4 | 0.0 | 1.0 | 0.0 | 0.0 |
| PLC | 0.9 | 3.4 | 3.2 | 3.1 | 1.9 | 0.0 | 4.9 | 16.3 | 1.8 | 0.02 | 0.7 |
| Calcineurin | 0.0 | 0.5 | 0.1 | 0.1 | 0.0 | 0.0 | 0.5 | 0.0 | 0.5 | 0.0 | 0.0 |
| Total % of patients with genetic variants5 | 5.91 | 13.9 | 23.0 | 20.3 | 22.2 | 24.1 | 39.0 | 48.8 | 11.9 | 2.33 | 26.5 |
This table provides a summary of data displayed in Figures 6 , 7 . The gene sets are listed in Supplemental Table 1 and the full list of cases reviewed is provided in Supplemental Table 2 (lymphoid cases) and Supplemental Table 3 (myeloid cases). 1,2,3,4 Patient numbers varied for these groups from the overall total as shown. 5Many patients had multiple genetic variants. AML, acute myeloid leukemia; B-ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MBL, monoclonal B-cell lymphocytosis; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms; PCM, plasma cell myeloma.